Tag: docetaxel
Phase 1/2 Clinical Trial Evaluates PDS0301 + Docetaxel in Patients Diagnosed...
A first study designed evaluate docetaxel, the current standard-of-care chemotherapy (SOC), in combination with PDS0301*, a novel antibody-drug conjugate or ADC, in patients diagnosed with metastatic castration sensitive (mCSPC) and castration resistant (mCRPC) prostate cancer, has shown a decrease in prostate specific antigen (PSA) levels in all patients participating in the clinical study.
MM-310 Maximizes the Delivery and Local Activation of a Newly Engineered...
Positive, preclinical data evaluating MM-310, an antibody directed nano therapeutic or ADN that encapsulates a newly engineered form of the highly potent chemotherapy docetaxel as a...
Ado-trastuzumab Emtansine Fails Phase II/III GATSBY trial
Earlier today, in a short statement to the U.S. Securities Exchange Commission (SEC), ImmunoGen, Inc. disclosed that the Phase II/III Gatsby trial, a clinical...
TARGET trial Shows Improved OS in Patients with FR+ Recurrent NSCLC...
The final overall survival (OS) analysis from the Phase IIb TARGET trial evaluating Endocyte's small molecule drug conjugate (SMDC) vintafolide in combination with docetaxel in...
FDA Rejects Accelerated Approval For T-DM1, Global Regulatory Submission Expected In...
Earlier today the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the Roche's trastuzumab-DM1 (T-DM1) Biologics...
